Dr. Thomas Patterson, chief of infectious disease, discusses the new antiviral drug, remdesivir, receiving emergency authorization by the FDA. Patterson is a local PI of the UT Health San Antonio study site in collaboration with University Hospital.
Newsroom
Dr. Thomas Patterson, chief of infectious disease, discusses the new antiviral drug, remdesivir, receiving emergency authorization by the FDA. Patterson is a local PI of the UT Health San Antonio study site in collaboration with University Hospital.